{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-082211","form_type":"8-K","ticker":"TAOX","cik":"0001571934","company_name":"TAO Synergies Inc.","filed_at":"2023-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.385522+00:00","generated_at":"2026-06-13T06:22:40.422704+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Synaptogenix partners with Cleveland Clinic for Phase 1 Bryostatin-1 trial in multiple sclerosis","bullets":["Agreement with Cleveland Clinic to conduct Phase 1 trial of Bryostatin-1 in multiple sclerosis; IND submission to FDA planned.","Trial expected to commence in Q4 2023 at Cleveland Clinic's Mellen Center for Multiple Sclerosis.","Synaptogenix had approximately $35.8M in cash as of March 31, 2023, sufficient to fund the trial and other developments.","Bryostatin-1 targets synaptic regeneration and anti-inflammatory pathways; cognitive impairment is a key unmet need in MS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-082211","json":"https://secwatch.observer/filing/0001104659-23-082211.json","markdown":"https://secwatch.observer/filing/0001104659-23-082211.md","text":"https://secwatch.observer/filing/0001104659-23-082211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1571934/000110465923082211/0001104659-23-082211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1571934/000110465923082211/tm2321611d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:22:40.422704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}